VACCINATION AGAINST HPV-ASSOCIATED DISEASES AND CERVICAL CANCER: THEORETICAL AND PRACTICAL ASPECTS

The article presents data about the frequency of the human papilloma virus associated pathology in the world, Europe and the RF increasing each year. The most frequently occurring pathologic states caused by human papilloma virus are provided. It was stated that the problem of HPV-associated diseases concerns not only women but men. The most frequent types of oncogenic viruses causing the malignant pathology of the reproductive system are Type 16 and 18 viruses. Vaccines providing prevention of the cervical cancer are developed for these two types of viruses. The quadrilent vaccine is effective with respect to lesions of the female genital organs and of the vagina in the form of condylomas. The article demonstrates the first results  of HPVvaccines in various countries of the world that testify about its high effectiveness for anogenital condylomas and precancer cervical changes, that considerably reduced in populations of such countries as Australia, Germany, Sweden etc. Issues on side effects related to application of both vaccines are discussed. Currently according to the conducted survey studies no safety problems were established for women and men when using quardilent as well as bivalent vaccines.

Currently vaccination against HPV is included in national immunization  programs in 60 countries of the world, including 6 countries where vaccination of boys is implemented.

In December 2014, FDA approved the new vaccine Gardasil-9 for girls and women as well as for boys for prevention of precancer lesions of reproductive organs the effectiveness of which is confirmed by results of international multi-center studies.

1. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol, 2002: 244-265;

2. Zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application Nat Rev Cancer, 2002: 342-350.

3. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol, 1999: 12-19.

4. Костин А.А. Анализ статистических данных о злокачественных новообразованиях, ассоциированных с вирусом папилломы человека. Исследования и практика в медицине. 2016, т. 3, с 66-78./Kostin A.A. Analysis of statistical data on malignant human papilloma virus associated lesions. Studies and practice in medicine. 2016, vol.3, p. 66-87.

5. X. Castellsagué et al. Vaccine 25, 2007: 27–219.

6. GM Clifford, S Gallus, R Herrero et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis Lancet, 366, 2005: 991-998.

7. DM Parkin The global health burden of infection-associated cancers in the year 2002 Int J Cancer, 118, 2006: 3030-3044.

8. GLOBOCAN 2010. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human pillomavirus and Related Cancers in World. Summary Report 2010. Accessed on 09/09/2012.Available at www. who. int/ hpvcentre.

9. Профилактика рака шейки матки. Под ред. Г.Т. Сухих и В.Н. Прилепской, 2012. / Cervical cancer prevention. Ed. by G.T. Sukhikh and V.N. Prilepskaya, 2012.

10. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24.

11. European Cervical Cancer Association. HPV vaccination across Europe. [Accessed 31 May 2009].

12. http://www.ecca.info/fileadmin/user_upload/HPV_Vaccination/ECCA_HPV_Vaccination_April_2009.pdf. Published 2009.

13. Immunise Australia Program. Human Papillomavirus (HPV). Department of Health and Ageing website. http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv.Accessed March 22, 2013.

14. National Advisory Committee on Immunization (NACI). Canada Comm Dis Rep. 2012;38:ACS http://www.phac-aspc.gc.ca/publicat/ccdrrmtc/12vol38/acs-dcc-1/assets/pdf/acs-dcc-1eng.pdf. Accessed March 22, 2013.

15. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries – an update. Stockholm: ECDC; 2012. http://www.ecdc.europa.eu/en/publications/publications/20120905_gui_hpv_vaccine_update.pdf. Accessed March 22, 2013.

16. Brotherton J et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-9

17. Powell SE et al. Vaccine. 2012;31:109–113

18. В.И. Краснопольский. Результаты вакцинопрофилактики ВПЧ-ассоциированных заболеваний и рака шейки матки в Московской области. Российский вестник акушерагинеколога 3, 2015./Krasnopolsky. Results of vaccine prevention of HPV-associated diseases and cervical cancer in the Moscow region. Rossiyskiy Vestnik Akushera-Ginekologa 3, 2015.

19. Saah A et al. presented at IPV 29.11-06.12.2012, Puerto-Rico

20. Harrington T. Presented at: National Foundation of Infectious Diseases 15th Annual Conference on Vaccine Research; 7–9 May, 2012;

21. Baltimore, MD. Atlanta, GA. Gardasil Pediatric Utilization and Safety Review for the Pediatric Advisory Committee Meeting – May 7-8, 2012.

22. Food and Drug Administrationwebsite. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM302352.pdf.

23. Joura EA et al. N Engl J Med. 2015; 372: 711-723.

24. GARDASIL 9 [summary of product characteristics]. Lyon, France: Sanofi Pasteur MSD SNC; 2015.